# A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors

> **NCT02516527** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 25 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02516527
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-16
- **Primary completion:** 2018-09-20
- **Final completion:** 2018-09-20
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02516527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02516527, "A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02516527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*